Catalent Plans $100M Expansion Of Biologics Capabilities At Italian Vaccine Plant


Catalent Inc CTLT will begin the first phase of a planned $100 million expansion at its facility in Anagni, Italy, to add biologics drug substance manufacturing capabilities

  • The plant is currently filling vials of COVID-19 vaccines for AstraZeneca plc AZN and Johnson & Johnson JNJ.
  • The company plans to install two 2,000-liter single-use bioreactors at the Anagni plant and the infrastructure required for another six 2,000-liter single-use bioreactors. 
  • The initial expansion is expected to be commissioned and operational in April 2023 and will increase the site's workforce by as many as 100 employees. 
  • Later phases of the planned expansion may include 16,000 liters of total flexible manufacturing capacity, enabling a 2,000-liter to 8,000-liter batch production scale.
  • Price Action: CTLT shares are up 0.28% at $113.00 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareGeneralBriefsCOVID-19 Vaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!